Yulia Maxuitenko

1.1k citations

46 papers · 775 indexed · h-index 16

Impact in

Pharmacology top 10%
- Inflammatory mediators and NSAID effects
Cancer Research

Papers in ⓘ

Molecular Biology 33
- Phosphodiesterase function and regulation 6
Oncology 19
- Peptidase Inhibition and Analysis 6
- HER2/EGFR in Cancer Research 5
- Pancreatic and Hepatic Oncology Research 5

Co-authors: Gary A. Piazza (25 shared papers)Adam B. Keeton (24 shared papers)Bill D. Roebuck (4 shared papers)Thomas W. Kensler (3 shared papers)Heather N. Tinsley (3 shared papers)Bernard D. Gary (3 shared papers)Jose Thaiparambil (2 shared papers)Yonghe Li (2 shared papers)
Journals: Cancer Research (10 papers)Journal of Clinical Oncology (4 papers)Cancer Chemotherapy and Pharmacology (3 papers)Cancer Prevention Research (2 papers)Carcinogenesis (2 papers)
Partner nations: United States United Kingdom Germany

In The Last Decade

Yulia Maxuitenko

41 papers receiving 756 citations

Peers

Countries citing papers authored by Yulia Maxuitenko

Since Specialization

Citations

This map shows the geographic impact of Yulia Maxuitenko's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yulia Maxuitenko with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yulia Maxuitenko more than expected).

Fields of papers citing papers by Yulia Maxuitenko

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yulia Maxuitenko. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yulia Maxuitenko. The network helps show where Yulia Maxuitenko may publish in the future.

Co-authors

The 25 scholars most cited alongside Yulia Maxuitenko, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Yulia Maxuitenko Line = papers co-authored together Yulia Maxuitenko links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 46 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	A Novel Sulindac Derivative That Does Not Inhibit Cyclooxygenases but Potently Inhibits Colon Tumor Cell Growth and Induces Apoptosis with Antitumor Activity Cancer Prevention Research ·Gary A. Piazza, Adam B. Keeton, Heather N. Tinsley, Bernard D. Gary, Jason Whitt, Bini Mathew, Jose Thaiparambil, Lori Coward, Gregory S. Gorman, Yonghe Li, Brahma P. Sani, Judith V. Hobrath, Yulia Maxuitenko, Robert C. Reynolds	2009	79
2	Colon Tumor Cell Growth–Inhibitory Activity of Sulindac Sulfide and Other Nonsteroidal Anti-Inflammatory Drugs Is Associated with Phosphodiesterase 5 Inhibition Cancer Prevention Research ·Heather N. Tinsley, Bernard D. Gary, Jose Thaiparambil, Li Nan, Wenyan Lü, Yonghe Li, Yulia Maxuitenko, Adam B. Keeton, Gary A. Piazza	2010	76
3	Transient intervention with oltipraz protects against aflatoxin-induced hepatic tumorigenesis. PubMed ·M.G. Bolton, Álvaro Muñoz, Lisa P. Jacobson, John D. Groopman, Yulia Maxuitenko, Bill D. Roebuck, Thomas W. Kensler	1993	75
4	Sorafenib is efficacious and tolerated in combination with cytotoxic or cytostatic agents in preclinical models of human non-small cell lung carcinoma Cancer Chemotherapy and Pharmacology ·Christopher A. Carter, Charles Chen, Cheryl Brink, Patrick W. Vincent, Yulia Maxuitenko, Karen S. Gilbert, William R. Waud, Xiaomei Zhang	2006	70
5	Identification of dithiolethiones with better chemopreventive properties than oltipraz Carcinogenesis ·Yulia Maxuitenko	1998	63
6	Novel DNA methyltransferase-1 (DNMT1) depleting anticancer nucleosides, 4′-thio-2′-deoxycytidine and 5-aza-4′-thio-2′-deoxycytidine Cancer Chemotherapy and Pharmacology ·Jaideep V. Thottassery, Vijaya Sambandam, Paula W. Allan, Joseph A. Maddry, Yulia Maxuitenko, K.P. Tiwari, Melinda G. Hollingshead, William B. Parker	2014	53
7	PDE5 and PDE10 inhibition activates cGMP/PKG signaling to block Wnt/β-catenin transcription, cancer cell growth, and tumor immunity Drug Discovery Today ·Gary A. Piazza, Antonio Ward, Xi Chen, Yulia Maxuitenko, Alexander B. Coley, Nada S. Aboelella, Donald J. Buchsbaum, Michael R. Boyd, Adam B. Keeton, Gang Zhou	2020	51
8	A novel polyamine analog (SL-11093) inhibits growth of human prostate tumor xenografts in nude mice Cancer Chemotherapy and Pharmacology ·Benjamín Frydman, Carl W. Porter, Yulia Maxuitenko, Aparajita Sarkar, Subhra Bhattacharya, Aldonia Valasinas, Venodhar K. Reddy, Nick Kisiel, Laurence J. Marton, Hirak S. Basu	2003	35
9	Vascular Endothelial Growth Factor Reduces Tamoxifen Efficacy and Promotes Metastatic Colonization and Desmoplasia in Breast Tumors Cancer Research ·Zhican Qu, Sabrina van Ginkel, Anshu M. Roy, Louise Westbrook, Mubina Nasrin, Yulia Maxuitenko, Andra R. Frost, Delicia Carey, Wenquan Wang, Rongbao Li, William E. Grizzle, Jaideep V. Thottassery, Florian Kern	2008	33
10	SHORT COMMUNICATION: Evaluation of the post-initiation effects of oltipraz on aflatoxin B₁-induced preneoplastic foci in a rat model of hepatic tumorigenesis Carcinogenesis ·Yulia Maxuitenko, Denise L. MacMillan, Thomas W. Kensler, Bill D. Roebuck	1993	30
11	Protection against Aflatoxin B1-Induced Hepatic Toxicity as a Short-Term Screen of Cancer Chemopreventive Dithiolethiones Fundamental and Applied Toxicology ·Yulia Maxuitenko	1996	22
12	Exploiting RAS Nucleotide Cycling as a Strategy for Drugging RAS-Driven Cancers International Journal of Molecular Sciences ·Tyler Mattox, Xi Chen, Yulia Maxuitenko, Adam B. Keeton, Gary A. Piazza	2019	22
13	Cyclopropane-Containing Polyamine Analogues Are Efficient Growth Inhibitors of a Human Prostate Tumor Xenograft in Nude Mice Journal of Medicinal Chemistry ·Benjamín Frydman, Andrei V. Blokhin, Sara Brummel, George Wilding, Yulia Maxuitenko, Aparajita Sarkar, Subhra Bhattacharya, Dawn R. Church, Venodhar K. Reddy, John A. Kink, Laurence J. Marton, Aldonia Valasinas, Hirak S. Basu	2003	22
14	Pharmacological inhibition of ABCC3 slows tumour progression in animal models of pancreatic cancer Journal of Experimental & Clinical Cancer Research ·Aleksandra Adamska, Alice Domenichini, Emily Capone, Verena Damiani, Begum Gokcen Akkaya, Kenneth J. Linton, Pierluigi Di Sebastiano, Xi Chen, Adam B. Keeton, Verónica Ramírez‐Alcántara, Yulia Maxuitenko, Gary A. Piazza, Vincenzo De Laurenzi, Gianluca Sala, Marco Falasca	2019	21
15	From Celecoxib to a Novel Class of Phosphodiesterase 5 Inhibitors: Trisubstituted Pyrazolines as Novel Phosphodiesterase 5 Inhibitors with Extremely High Potency and Phosphodiesterase Isozyme Selectivity Journal of Medicinal Chemistry ·Mohammad Abdel‐Halim, Sara Sigler, Nora A. S. Racheed, Amr Hefnawy, Reem K. Fathalla, Mennatallah A. Hammam, Ahmed Maher, Yulia Maxuitenko, Adam B. Keeton, Rolf W. Hartmann, Matthias Engel, Gary A. Piazza, Alireza Abadi	2021	19
16	Enhancing anticancer activity of checkpoint immunotherapy by targeting RAS SHILAP Revista de lepidopterología ·Antonio Ward, Adam B. Keeton, Xi Chen, Tyler Mattox, Alexander B. Coley, Yulia Maxuitenko, Donald J. Buchsbaum, Troy D. Randall, Gang Zhou, Gary A. Piazza	2020	18
17	Inhibition of the Lysophosphatidylinositol Transporter ABCC1 Reduces Prostate Cancer Cell Growth and Sensitizes to Chemotherapy Cancers ·Aikaterini Emmanouilidi, Ilaria Casari, Begum Gokcen Akkaya, Tania Maffucci, Luc Furic, Federica Guffanti, Massimo Broggini, Xi Chen, Yulia Maxuitenko, Adam B. Keeton, Gary A. Piazza, Kenneth J. Linton, Marco Falasca	2020	12
18	Pan-RAS inhibitors: Hitting multiple RAS isozymes with one stone Advances in cancer research ·Alexander B. Coley, Antonio Ward, Adam B. Keeton, Xi Chen, Yulia Maxuitenko, Aishwarya Prakash, Feng Li, Jeremy B. Foote, Donald J. Buchsbaum, Gary A. Piazza	2022	9
19	Urinary taurine as a non-invasive marker of aflatoxin B1-induced hepatotoxicity: success and failure Toxicology ·Yulia Maxuitenko, William G. North, Bill D. Roebuck	1997	8
20	Establishment of a mammary carcinoma cell line from Syrian hamsters treated with N-methyl-N-nitrosourea Cancer Letters ·Malari A. Coburn, Sabrina Brueggemann, Shilpa Bhatia, Bing Cheng, Benjamin D.�L. Li, Xiao Lin Li, Natalia Luraguiz, Yulia Maxuitenko, Elysse A. Orchard, Songlin Zhang, Mariam A. Stoff‐Khalili, J. Michael Mathis, Heather E Kleiner‐Hancock	2011	6

About Yulia Maxuitenko

Yulia Maxuitenko is a scholar working on Molecular Biology, Oncology, Pharmacology, Organic Chemistry and Genetics, having authored 46 papers that have together received 775 indexed citations. Recurring topics across this work include Inflammatory mediators and NSAID effects (8 papers), Phosphodiesterase function and regulation (6 papers), Estrogen and related hormone effects (6 papers), Peptidase Inhibition and Analysis (6 papers), Synthesis and biological activity (6 papers), Cancer Research and Treatments (5 papers), HER2/EGFR in Cancer Research (5 papers) and Pancreatic and Hepatic Oncology Research (5 papers). The work is most often cited by research in Pharmacology (143 citations), Cancer Research (119 citations), Toxicology (24 citations), Molecular Biology (479 citations) and Biochemistry (50 citations). Yulia Maxuitenko has collaborated with scholars based in United States, United Kingdom and Germany. Frequent co-authors include Gary A. Piazza, Adam B. Keeton, Bill D. Roebuck, Thomas W. Kensler, Heather N. Tinsley, Bernard D. Gary, Jose Thaiparambil, Yonghe Li, Lisa P. Jacobson and Álvaro Muñoz. Their work appears in journals such as Cancer Research, Journal of Clinical Oncology, Cancer Chemotherapy and Pharmacology, Cancer Prevention Research and Carcinogenesis.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact